Immune Network nears patent for HIV antibody:
This article was originally published in Clinica
Canada's Immune Network has received a notice of allowance on two US patents related to its 1F7 technology for HIV diagnosis and treatment. The patents, when issued, will cover the Vancouver, British Columbia firm's anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related diseases. Immune Network recently announced that biopharmaceutical firm AbNovo had acquired a licence option on the 1F7 technology as well as on the company's anti-HIV monoclonal antibody, hNM01.